Procter&Gamble and Intrinsa

More than 5 billion people in over 180 countries worldwide get acquainted with Procter&Gamble products every day of their lives. P&G has become the expression of pragmatism, utility, comfort and, more importantly, quality aiming to satisfy its consumers' expectations.

Procter&Gamble has succeeded so far to improve household and family care respecting values like leadership, ownership, integrity, trust and a good taste for winning all competitions. Products like Vicks(R), Pepto-bismol(R), Metamucil(R), Thermacare(R), Pampers(R), Ariel(R), Always(R), Pantene(R), Herbal Essences(R), Fairy(R), Ace(R), Lenor(R), M. Proper(R), Tampax(R) or Pringles(R) are some of P&G's reasons of pride.
P&G Pharmaceuticals labels over-the-counter medications, oral care products and other health destined products. The specialists in P&G combine experience, dedication, development and marketing aiming to enrich and improve world's medical market. The results of their research are labeled and known as Actonel(R), Asacol(R), Dantrium(R), Didronel(R), Macrobid(R), Macrodantin(R).

Although Procter&Gamble is testing its new release, Intrinsa, only on surgically menopausal women at the present time, the target is the naturally menopausal female subjects which are a real consistent market of the product. Even though statistics indicate an approximate rate of 40% sexually impaired women, the percentage of women who might purchase Intrinsa is still uncertain. Nonetheless, the manufacturer of the testosterone skin patch must face the competition who tries to release similar products but supplied as a cream, pill, nasal spray or lotion gel. The advantage of Proctor&Gamble is, however, the relatively big advantage of 18 to 24 month over these smaller companies among which Virus, BioSante Pharmaceuticals or NexMed.
P&G's spoke persons declared they expect to release Intrinsa in 2005 or 2006 the latest. The company's highest hopes are to launch the testosterone skin patch in mid 2005. Marketing experts estimate sales on Intrinsa of $250 million up to $300 million for the years 2007 and 2008 without considering the European market. The potential of the U.S. female market certifies expectations .10% of the nearly 10 million American surgically menopausal women deal with the precise symptomalogy of hypoactive sexual desire disorder. Moreover, 16% of the 30 million naturally menopausal females also reported FSD reactions.

The Food and Dug Administration Advisory Committee, however, reveals serious concerns about the potential adverse reactions involved by hormonal therapy and shows great interest in longer-term more specific surveys which might bring along Intrinsa's approval in the near future.